RESUMEN
BACKGROUND: Invasive pneumococcal disease (IPD) remains a significant concern among children under 5, despite vaccination efforts. This study assessed IPD prevalence and associated risks in pediatric population. METHODS: An observational, retrospective, multicenter study in Comunidad Valenciana, Spain, of IPD cases in children under 13 from January 2012 to September 2022. Data from the CV Microbiology Surveillance Network (RedMIVA) and medical records were reviewed. RESULTS: A total of 379 IPD cases in 377 patients were analyzed, predominantly males (54.11 %) under 5 (81.17 %). PCV13 vaccination notably reduced PCV13-serotypes IPD (p=0.0002), except serotype 3. Pneumonia was common, with half having underlying conditions (50.40 %). Worse outcomes occurred in patients with neurological disorders (ANOVA, p=0.57). Vaccine failures often involved underlying conditions (63 %) and serotypes 3 and 19A. Immunodeficiencies may relate to recurrent IPD, but evidence is limited. CONCLUSION: Despite vaccination, IPD still impacts children, influenced by immunological status, affecting severity and mortality.
RESUMEN
Measurement of anti-pneumococcal capsular polysaccharides (anti-PnPs) IgG titers is an important tool in the immunologic assessment of patients with suspected immunodeficiency disorders (ID) to reduce the morbi-mortality and minimize severe infections. Retrospectively, we studied the relationship among anti-PnPs IgG response to 3 doses of Prevenar®13, levels of immune system components, leukocyte populations, and clinical data in children with ID. Serum samples were collected at least 4 weeks post vaccination. Subsequently, multi-serotype enzyme-linked immunosorbent assay (ELISA) was performed. Eighty-seven children (under 12 years) were enrolled. Primary immunodeficiency disorder (PID) was the most common disorder (45) followed by possible immunodeficiency disorder (POID) (19), secondary immunodeficiency disorder (SID) (15), and mixed immunodeficiency disorder (MID) (8). The median age was 3 (1.50-5.33) years, 65% of patients were male. Deficient production of anti-PnPs IgG (titer ≤ 50 mg/L) was detected in 47 patients (54%), especially in the MID group, all of them under immunosuppressive therapy. In PCV13 responders, the mean of leukocyte population levels was higher with statistically significance differences in CD4 + /CD8 + T lymphocytes (p = 0.372, p = 0.014) and CD56 + /CD16 + NK (p = 0.016). Patients with previous bone marrow transplantation were the worst PCV13 responders. Pneumococcal IgG antibody titers (post-vaccination) along with clinical and analytical markers represented.
Asunto(s)
Formación de Anticuerpos , Vacunas Neumococicas , Preescolar , Femenino , Humanos , Masculino , Anticuerpos Antibacterianos , Vacuna Neumocócica Conjugada Heptavalente , Inmunoglobulina G , Estudios Retrospectivos , Streptococcus pneumoniae , LactanteRESUMEN
Incidence of pneumococcal disease has increased worldwide in recent years. Response to pneumococcal vaccine is usually measured using the multiserotype enzyme-linked immunosorbent assay (ELISA) pneumococcal test. However, this approach presents several limitations. Therefore, the introduction of new and more robust analytical approaches able to provide information on the efficacy of the pneumococcal vaccine would be very beneficial for the clinical management of patients. Surface plasmon resonance (SPR) has been shown to offer a valuable understanding of vaccines' properties over the last years. The aim of this study is to evaluate the reliability of SPR for the anti-pneumococcal capsular polysaccharides (anti-PnPs) IgGs quantification in vaccinated. Fast protein liquid chromatography (FPLC) was used for the isolation of total IgGs from serum samples of vaccinated patients. Binding-SPR assays were performed to study the interaction between anti-PnPs IgGs and PCV13. A robust correlation was found between serum levels of anti-PnPs IgGs, measured by ELISA, and the SPR signal. Moreover, it was possible to correctly classify patients into "non-responder", "responder" and "high-responder" groups according to their specific SPR PCV13 response profiles. SPR technology provides a valuable tool for reliably characterize the interaction between anti-PnPs IgGs and PCV13 in a very short experimental time.
Asunto(s)
Inmunogenicidad Vacunal , Vacunas Neumococicas/inmunología , Resonancia por Plasmón de Superficie/métodos , Adulto , Humanos , Inmunoglobulina G/sangre , Inmunoglobulina G/inmunología , Persona de Mediana EdadRESUMEN
BACKGROUND: Leishmaniasis, considered by the World Health Organization as one of the most important tropical diseases, is endemic in the Mediterranean Basin. The aim of this study was to evaluate epidemiological and clinical characteristics of cutaneous (CL) and mucocutaneous leishmaniasis (MCL) in La Fe University Hospital, Valencia, Spain. The particular focus was on diagnosis techniques and clinical differences according to the immunological status of the patients. METHODS: An eleven-year retrospective observational study of CL and MCL episodes at the hospital was performed. Epidemiological, clinical and therapeutic variables of each case, together with the microbiological and anatomopathological diagnosis, were analyzed. RESULTS: A total of 42 patients were included, 30 of them were male and 28 were immunocompetent. Most of the cases (36/42) were diagnosed in the last 5 years (2013-2017). The incidence of CL and MCL increased from 3.6/100,000 (2006-2012) to 13.58/100,000 (2013-2017). The majority of the patients (37/42) exhibited CL, in 30 cases as single lesions (30/37). Ulcerative lesions were more common in immunosuppressed patients (13/14) than in immunocompetent patients (20/28), (P = 0.2302). The length of lesion presence before diagnosis was 7.36 ± 6.72 months in immunocompetent patients and 8.79 ± 6.9 months in immunosuppressed patients (P = 0.1863). Leishmania DNA detection (92.3%) was the most sensitive diagnostic technique followed by Giemsa stain (65%) and histopathological examination (53.8%). Twelve patients (12/42) had close contact with dogs or were living near to kennels, and 10 of them did not present underlying conditions. Intralesional glucantime (21/42) and liposomal amphotericin B (7/42) were the most common treatments administered in monotherapy. All patients evolved successfully and no relapse was reported. CONCLUSIONS: Some interesting clinical and epidemiological differences were found in our series between immunocompetent and immunosuppressed patients. Future studies can take these results further especially by studying patients with biological therapy. Skin biopsies combining NAAT with histological techniques are the most productive techniques for CL or MCL diagnosis.
Asunto(s)
Leishmania/efectos de los fármacos , Leishmaniasis Cutánea , Leishmaniasis Mucocutánea , Administración Cutánea , Adolescente , Adulto , Anciano , Anfotericina B/administración & dosificación , Niño , Preescolar , Femenino , Humanos , Huésped Inmunocomprometido , Leishmania/aislamiento & purificación , Leishmaniasis Cutánea/diagnóstico , Leishmaniasis Cutánea/tratamiento farmacológico , Leishmaniasis Cutánea/inmunología , Leishmaniasis Cutánea/patología , Leishmaniasis Mucocutánea/diagnóstico , Leishmaniasis Mucocutánea/tratamiento farmacológico , Leishmaniasis Mucocutánea/inmunología , Leishmaniasis Mucocutánea/patología , Masculino , Antimoniato de Meglumina/administración & dosificación , Persona de Mediana Edad , Estudios Retrospectivos , Factores de Riesgo , España/epidemiología , Adulto JovenRESUMEN
Introducción: La malaria es considerada la cuarta causa de mortalidad infantil después de la neumonía, las complicaciones por parto prematuro y la asfixia perinatal. Material y métodos: Estudio retrospectivo y descriptivo de los casos de paludismo confirmados y tratados en la Unidad de Enfermedades Infecciosas Pediátricas (edad inferior a 15 años) del Hospital La Fe (Valencia) en el período comprendido entre 1993 y 2015. Resultados: Durante el período 1993-2015 se diagnosticaron 54 casos de malaria infantil, el 51,8% en varones. El 46,2% eran menores de 5 años. La mayoría de los niños procedían de Guinea Ecuatorial (68,5%). Solo en el 5,6% de los pacientes se pudo constatar que recibieran profilaxis antimalárica. Se evidenció que Plasmodium falciparum fue la especie causal del 81,4% de los episodios. Siete casos (13%) presentaron malaria complicada. El tratamiento más empleado fue la quinina, sola o en combinación con otros fármacos: atovacuona-proguanil fue empleada a partir del año 2010 y estuvo indicada en el 20,3% de los pacientes. A partir del año 2013 se inició la utilización de: artesunato, piperaquina y dihidroartemisina. No hubo mortalidad ni efectos adversos relevantes, siendo la respuesta clínica favorable en el 100% de los niños. Conclusiones: La malaria sigue siendo una enfermedad vigente en nuestra población, consecuencia de la inmigración y del turismo a países endémicos. Debe ser considerada como diagnóstico probable ante un niño febril que procede o ha viajado a un área endémica en el último año
Introduction: Malaria is considered to be the fourth leading cause of infant mortality after pneumonia, complications related to premature birth, and perinatal asphyxia. Material and methods: A retrospective and descriptive study of cases of malaria confirmed and treated by the Paediatric Infectious Diseases Unit (age lower than 15 years) at the La Fe Hospital, Valencia, over the period 1993 to 2015. Results: A total of 54 cases of paediatric malaria were diagnosed in the period 1993-2015, with 51.8% of these occurring in males, and 46.2% of patients were aged below 5 years. The majority of children came from Equatorial Guinea (68.5%). Only 5.6% had received antimalarial prophylaxis. Plasmodium falciparum was found to be the causal species in 81.4% of cases. Seven patients (13%) presented with complicated malaria. The most widely used treatment was quinine, either alone or in combination with other drugs. Atovaquone/proguanil was used from 2010 onwards and was indicated in 20.3% of the patients. The combination of artesunate/piperaquine/dihydroartemisinin began to be used in 2013. No deaths or relevant side effects were reported, and the clinical response was favourable in all children (100%). Conclusions: Malaria is still a prevalent disease in this population, a consequence of immigration, and tourism to endemic countries. Malaria should be considered as a likely diagnosis in a febrile child who comes from, or has travelled to, an endemic region in the past year
Asunto(s)
Humanos , Masculino , Femenino , Preescolar , Niño , Malaria/epidemiología , Malaria/microbiología , España/epidemiología , Estudios Retrospectivos , Epidemiología Descriptiva , Malaria/etiología , Malaria/tratamiento farmacológicoRESUMEN
INTRODUCTION: Malaria is considered to be the fourth leading cause of infant mortality after pneumonia, complications related to premature birth, and perinatal asphyxia. MATERIAL AND METHODS: A retrospective and descriptive study of cases of malaria confirmed and treated by the Paediatric Infectious Diseases Unit (age lower than 15 years) at the La Fe Hospital, Valencia, over the period 1993 to 2015. RESULTS: A total of 54 cases of paediatric malaria were diagnosed in the period 1993-2015, with 51.8% of these occurring in males, and 46.2% of patients were aged below 5 years. The majority of children came from Equatorial Guinea (68.5%). Only 5.6% had received antimalarial prophylaxis. Plasmodium falciparum was found to be the causal species in 81.4% of cases. Seven patients (13%) presented with complicated malaria. The most widely used treatment was quinine, either alone or in combination with other drugs. Atovaquone/proguanil was used from 2010 onwards and was indicated in 20.3% of the patients. The combination of artesunate/piperaquine/dihydroartemisinin began to be used in 2013. No deaths or relevant side effects were reported, and the clinical response was favourable in all children (100%). CONCLUSIONS: Malaria is still a prevalent disease in this population, a consequence of immigration, and tourism to endemic countries. Malaria should be considered as a likely diagnosis in a febrile child who comes from, or has travelled to, an endemic region in the past year.
Asunto(s)
Malaria/epidemiología , Adolescente , Distribución por Edad , Antimaláricos/uso terapéutico , Artemisininas/uso terapéutico , Artesunato/uso terapéutico , Atovacuona/uso terapéutico , Niño , Preescolar , Combinación de Medicamentos , Guinea Ecuatorial/etnología , Femenino , Hospitales Comunitarios/estadística & datos numéricos , Humanos , Lactante , Malaria/complicaciones , Malaria/tratamiento farmacológico , Masculino , Proguanil/uso terapéutico , Quinina/uso terapéutico , Quinolinas/uso terapéutico , Estudios Retrospectivos , Distribución por Sexo , España/epidemiología , Evaluación de SíntomasRESUMEN
No disponible
Asunto(s)
Humanos , Masculino , Anciano , Absceso Abdominal/microbiología , Infecciones por Bacterias Grampositivas/microbiología , Cocos Anaerobios Gramnegativos/aislamiento & purificación , Infecciones Oportunistas/microbiología , Pielonefritis/microbiología , Absceso Abdominal/diagnóstico , Absceso Abdominal/etiología , Antibacterianos/uso terapéutico , Bacteriemia , Clindamicina/uso terapéutico , Placa Dental/microbiología , Diagnóstico Precoz , Ertapenem/uso terapéutico , Infecciones por Bacterias Grampositivas/tratamiento farmacológico , Infecciones por Bacterias Grampositivas/etiologíaAsunto(s)
Absceso Abdominal/microbiología , Infecciones por Bacterias Grampositivas/microbiología , Cocos Grampositivos/aislamiento & purificación , Infecciones Oportunistas/microbiología , Pielonefritis/microbiología , Absceso Abdominal/diagnóstico , Absceso Abdominal/tratamiento farmacológico , Absceso Abdominal/etiología , Anciano , Antibacterianos/uso terapéutico , Bacteriemia/diagnóstico , Bacteriemia/tratamiento farmacológico , Bacteriemia/etiología , Bacteriemia/microbiología , Clindamicina/uso terapéutico , Placa Dental/microbiología , Diagnóstico Precoz , Ertapenem/uso terapéutico , Infecciones por Bacterias Grampositivas/diagnóstico , Infecciones por Bacterias Grampositivas/tratamiento farmacológico , Infecciones por Bacterias Grampositivas/etiología , Humanos , Masculino , Infecciones Oportunistas/diagnóstico , Infecciones Oportunistas/tratamiento farmacológico , Infecciones Oportunistas/etiología , Complicaciones Posoperatorias/diagnóstico , Complicaciones Posoperatorias/tratamiento farmacológico , Complicaciones Posoperatorias/microbiología , Pielonefritis/diagnóstico , Pielonefritis/tratamiento farmacológico , Pielonefritis/etiología , Extracción DentalRESUMEN
No disponible
Asunto(s)
Humanos , Masculino , Persona de Mediana Edad , Enfermedades de la Piel/inmunología , Enfermedades de la Piel/patología , Leucemia Mieloide Aguda/inmunología , Cabeza , Resultado Fatal , Necrosis/inmunología , Necrosis/patologíaRESUMEN
No disponible
Asunto(s)
Humanos , Femenino , Adulto , Enfermedad Inflamatoria Pélvica/diagnóstico , Enfermedad Inflamatoria Pélvica/microbiología , Infecciones Neumocócicas/diagnóstico , Streptococcus pneumoniae , EndosonografíaRESUMEN
No disponible
Asunto(s)
Humanos , Masculino , Anciano , Eritema/etiología , Trasplante de Pulmón , Alternaria/aislamiento & purificación , Alternariosis/diagnóstico , BiopsiaAsunto(s)
Alternariosis/diagnóstico , Huésped Inmunocomprometido , Trasplante de Pulmón , Complicaciones Posoperatorias/diagnóstico , Anciano , Alternariosis/etiología , Alternariosis/inmunología , Alternariosis/patología , Humanos , Pierna , Masculino , Complicaciones Posoperatorias/inmunología , Complicaciones Posoperatorias/patologíaRESUMEN
No disponible